Bristol-Myers Squibb
BMY
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Seeking Alpha • 1 day ago • BMY
Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)
Seeking Alpha • 2 days ago • BMY
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
Benzinga • 3 days ago • BMY
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Zacks Investment Research • 3 days ago • BMY
Is BMY's Deep Pipeline the Key to Its Next Growth Phase?
Reuters • 3 days ago • BMY
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.